- Mangoceuticals (NASDAQ:MGRX) on Friday said its unit, MangoRx Mexico, executed a technical agreement with Emifarma for the initial stages of development and testing of the company’s erectile dysfunction products intended for the Mexican and Latin American markets.
- "Establishing a pharmaceutical manufacturing partner was the catalyst necessary to begin product development for testing as required for the application and certification with the Comisión Federal para la Protección contra Riesgos Sanitarios," said CEO Jacob Cohen.
- "Assuming such approval is obtained, we expect to be able to start marketing and selling our Mango ED products to the more than 40,000 pharmacies, retail outlets, and convenience stores across Mexico," the CEO added.
- Source: Press Release